Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 28, 2023
Expiration Date: March 28, 2024
Description:
Prostate cancer is the leading type of cancer among men. Prostate cancer recurrence after curative-intent treatment occurs in 30% to 50% of patients in the first 10 years after initial therapy. Traditionally, conventional prostate cancer imaging based on MRI, bone scanning, and CT has shown low sensitivity for biochemical recurrence, especially at low PSA levels.
Medical Crossfire®, one of PER®’s signature educational formats, is both an in-person and virtual program during which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding current and emerging therapeutic strategies supporting the use of prostate-specific membrane antigen (PSMA)–directed strategies for the diagnosis (PSMA-targeted imaging techniques) and management (PSMA-radioligand therapy) of prostate cancer.
This educational activity is an archive of the live virtual symposium, which was held on February 15, 2023.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Describe unmet clinical needs in the management of prostate cancer in the context of novel PSMA-directed strategies in diagnosis and management of prostate cancer
• Assess emerging clinical trial evidence on evolving PSMA-targeting strategies and its potential implications on evolving treatment paradigms in metastatic castration-resistant prostate cancer (mCRPC)
• Determine effective approaches to integrate and sequence PSMA-targeting radioligand strategies into current clinical practice to manage patients with mCRPC
• Discuss potential multidisciplinary strategies to recognize and manage toxicities associated with currently approved as well as emerging PSMA-directed therapies for mCRPC care